Capula Management LTD Bristol Myers Squibb CO Call Options Transaction History

Capula Management LTD

13 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 14, 2023	BUY	$63.71 - $70.74 $4.94 Million - $5.49 Million	77,600 Added 63.4%	200,000 $12.8 Million
Q1 2023 May 10, 2023	SELL	$65.71 - $74.53 $9.11 Million - $10.3 Million	-138,600 Reduced 53.1%	122,400 $8.48 Million
Q4 2022 Feb 14, 2023	SELL	$68.48 - $81.09 $25.9 Million - $30.6 Million	-377,900 Reduced 59.15%	261,000 $18.8 Million
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $53,183 - $31.4 Million	-409,100 Reduced 39.04%	638,900 $45.4 Million
Q2 2022 Aug 15, 2022	BUY	$72.62 - $79.98 $32.5 Million - $35.8 Million	448,000 Added 74.67%	1,048,000 $80.7 Million
Q1 2022 May 17, 2022	BUY	$61.48 - $73.72 $36.9 Million - $44.2 Million	600,000 New	600,000 $43.8 Million
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $4.52 Million - $5.26 Million	-84,200 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $3.03 Million - $3.55 Million	51,200 Added 155.15%	84,200 $4.98 Million
Q1 2021 May 14, 2021	SELL	$59.34 - $66.74 $7.54 Million - $8.48 Million	-127,000 Reduced 79.38%	33,000 $2.08 Million
Q4 2020 Feb 16, 2021	BUY	$57.74 - $65.43 $8.76 Million - $9.93 Million	151,800 Added 1851.22%	160,000 $9.93 Million
Q2 2020 Aug 14, 2020	SELL	$54.82 - $64.09 $30.2 Million - $35.4 Million	-551,800 Reduced 98.54%	8,200 $482,000
Q1 2020 May 15, 2020	BUY	$46.4 - $67.43 $24.4 Million - $35.4 Million	525,000 Added 1500.0%	560,000 $31.2 Million
Q4 2019 Feb 14, 2020	BUY	$49.21 - $64.19 $1.72 Million - $2.25 Million	35,000 New	35,000 $2.25 Million

2,536

1.46B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $121B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Capula Management LTD, based on Form 13F filings with the SEC.

Stay updated on Capula Management LTD with notifications on news.